- Benzinga
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after ending 2023 with good news from its combined treatment with Moderna Inc (NASDAQ: MRNA) in fighting melanoma. Merck reported improvement in cancer patients receiving its Keytruda regimen. Enrolling 698 subjects, the trial evaluated the effect of a treatment that combines Merck’s immunotherapy blockb
- AFP
Hamilton says Newey would be 'amazing addition' for Ferrari
Lewis Hamilton added fuel to the rumours over the future of departing Red Bull designer Adrian Newey saying on Thursday that he would be an "amazing addition" for his future team Ferrari."I think he would be an amazing addition," he added.
- Reuters
UPDATE 1-More funds needed for US telecoms to remove Chinese equipment, says FCC
The Federal Communications Commission (FCC) said on Thursday nearly 40% of U.S. telecom companies getting federal support need additional government funding to remove equipment made by Chinese telecoms firms Huawei and ZTE from American wireless networks to address security risks. The FCC said removing the equipment is estimated to cost $4.98 billion but Congress has only approved $1.9 billion for the "rip and replace" program. FCC Chair Jessica Rosenworcel on Thursday called on Congress for urgent additional funding, warning some carriers in the reimbursement program have told the FCC recently "that they foresee significant consequences that could result from the lack of full funding, including having to shut down their networks."
